4.6 (611) In stock
U.S. Patent Application 20190241896 for Modulators Of Dnm2 Expression
WO2019089692A1 - MODULATORS OF ENaC EXPRESSION - Google Patents
EP0777674B1 - Polynucleotide reagents having nonnucleotidic moieties, and associated methods of synthesis and use - Google Patents
Molecular probes for the human adenosine receptors
A DNM2 Centronuclear Myopathy Mutation Reveals a Link between Recycling Endosome Scission and Autophagy - ScienceDirect
A DNM2 Centronuclear Myopathy Mutation Reveals a Link between Recycling Endosome Scission and Autophagy - ScienceDirect
Modulators Of Dnm2 Expression Freier; Susan M. ; et al. [Ionis Pharmaceuticals, Inc.]
Modulators Of Dnm2 Expression Freier; Susan M. ; et al. [Ionis Pharmaceuticals, Inc.]
Differential impact of ubiquitous and muscle dynamin 2 isoforms in muscle physiology and centronuclear myopathy
EP0348458B1 - Dna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
A DNM2 Centronuclear Myopathy Mutation Reveals a Link between Recycling Endosome Scission and Autophagy - ScienceDirect
EP0517796B1 - Oligonucleotide analogs - Google Patents
WO1992005186A1 - Modified internucleoside linkages - Google Patents
JCI Insight - Physiological impact and disease reversion for the severe form of centronuclear myopathy linked to dynamin
WO2017053722A1 - Modulators of kras expression - Google Patents
A Combination of Native LC-MS Approaches for the Comprehensive Characterization of the Antibody-Drug Conjugate Trastuzumab Deruxtecan
